Evaluation of the significance of subcarinal lymph node dissection in stage IB non‑small cell lung cancer

Wang,Feng; Yu,Xiangyang; Han,Yi; Zhang,Lanjun; Liu,Shuku

doi:10.3892/mco.2023.2646

Evaluation of the significance of subcarinal lymph node dissection in stage IB non‑small cell lung cancer

Authors:
- Feng Wang
- Xiangyang Yu
- Yi Han
- Lanjun Zhang
- Shuku Liu
View Affiliations

Affiliations: Department of Minimally Invasive Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, P.R. China, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer, Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China, State Key Laboratory of Oncology in South China, Department of Thoracic Surgery, Collaborative Innovation Center for Cancer Medicine, Sun Yat‑sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China
Published online on: May 16, 2023 https://doi.org/10.3892/mco.2023.2646
Article Number: 50
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lymph node dissection is used to treat early‑stage lung cancer. The present study aimed to investigate if resecting the subcarinal lymph nodes affects prognosis of patients with stage IB non‑small cell lung cancer (NSCLC). A total of 597 patients with stage IB NSCLC who underwent lung cancer surgery at Sun Yat‑Sen University Cancer Center from January 1999 to December 2009 were included in the present study. The potential prognostic factors were evaluated using the Cox proportional hazard regression model. A total of 252 cases were obtained following propensity score matching (PSM). To compare overall survival (OS) and recurrence‑free survival (RFS), Kaplan‑Meier method and log‑rank test were used. Among the 597 cases included, 185 did not undergo subcarinal lymph node resection, whereas 412 did. There were statistically significant differences between the two groups in terms of bronchial invasion, number of resected lymph node stations and resected lymph node numbers (P<0.05). Age, family history of cancer and the number of resected lymph nodes were prognostic factors for OS, whereas age and the number of resected lymph nodes were prognostic factors for RFS (P<0.05). Resection of subcarinal lymph nodes was not associated with OS and RFS. After PSM, survival analysis was recalculated using the Kaplan‑Meier method and log‑rank test; subcarinal lymph node resection was not statistically associated with OS and RFS. (P>0.05). For stage IB NSCLC, there was no statistically significant association between subcarinal lymph node resection and OS and RFS. Subcarinal lymph node resection in surgery of stage IB NSCLC may be considered optional.

View Figures

View References

1	Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144:1941–1953. 2019.PubMed/NCBI View Article : Google Scholar
2	Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008.PubMed/NCBI View Article : Google Scholar
3	Masuda M, Kuwano H, Okumura M, Arai H, Endo S, Doki Y, Kobayashi J, Motomura N, Nishida H, Saiki Y, et al: Thoracic and cardiovascular surgery in Japan during 2013: Annual report by The Japanese association for thoracic surgery. Gen Thorac Cardiovasc Surg. 63:670–701. 2015.PubMed/NCBI View Article : Google Scholar
4	De Leyn P, Lardinois D, Van Schil P, Rami-Porta R, Passlick B, Zielinski M, Waller D, Lerut T and Weder W: European trends in preoperative and intraoperative nodal staging: ESTS guidelines. J Thorac Oncol. 2:357–361. 2007.PubMed/NCBI View Article : Google Scholar
5	Howington JA, Blum MG, Chang AC, Balekian AA and Murthy SC: Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 143:e278S–e313S. 2013.PubMed/NCBI View Article : Google Scholar
6	Ishiguro F, Matsuo K, Fukui T, Mori S, Hatooka S and Mitsudomi T: Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: A large-scale retrospective cohort study applying a propensity score. J Thorac Cardiovasc Surg. 139:1001–1006. 2010.PubMed/NCBI View Article : Google Scholar
7	Maniwa T, Okumura T, Isaka M, Nakagawa K, Ohde Y and Kondo H: Recurrence of mediastinal node cancer after lobe-specific systematic nodal dissection for non-small-cell lung cancer. Eur J Cardiothorac Surg. 44:e59–e64. 2013.PubMed/NCBI View Article : Google Scholar
8	Hishida T, Miyaoka E, Yokoi K, Tsuboi M, Asamura H, Kiura K, Takahashi K, Dosaka-Akita H, Kobayashi H, Date H, et al: Lobe-specific nodal dissection for clinical stage I and II NSCLC: Japanese multi-institutional retrospective study using a propensity score analysis. J Thorac Oncol. 11:1529–1537. 2016.PubMed/NCBI View Article : Google Scholar
9	Adachi H, Sakamaki K, Nishii T, Yamamoto T, Nagashima T, Ishikawa Y, Ando K, Yamanaka K, Watanabe K, Kumakiri Y, et al: Lobe-specific lymph node dissection as a standard procedure in surgery for non-small cell lung cancer: A propensity score matching study. J Thorac Oncol. 12:85–93. 2017.PubMed/NCBI View Article : Google Scholar
10	Okada M, Sakamoto T, Yuki T, Mimura T, Miyoshi K and Tsubota N: Selective mediastinal lymphadenectomy for clinico-surgical stage I non-small cell lung cancer. Ann Thorac Surg. 81:1028–1032. 2006.PubMed/NCBI View Article : Google Scholar
11	Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, Jones DR, McKenna RJ, Landreneau RJ, Rusch VW and Putnam JB Jr: Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: Results of the American college of surgery oncology group z0030 trial. J Thorac Cardiovasc Surg. 141:662–670. 2011.PubMed/NCBI View Article : Google Scholar
12	Hughes MJ, Chowdhry MF, Woolley SM and Walker WS: In patients undergoing lung resection for non-small cell lung cancer, is lymph node dissection or sampling superior? Interact Cardiovasc Thorac Surg. 13:311–315. 2011.PubMed/NCBI View Article : Google Scholar
13	Li H, Han D, Hou Y, Chen H and Chen Z: Statistical inference methods for two crossing survival curves: A comparison of methods. PLoS One. 10(e0116774)2015.PubMed/NCBI View Article : Google Scholar
14	Lardinois D, De Leyn P, Van Schil P, Porta RR, Waller D, Passlick B, Zielinski M, Lerut T and Weder W: ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg. 30:787–792. 2006.PubMed/NCBI View Article : Google Scholar
15	Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, Opitz I, Call S, Hasegawa S, Kernstine K, et al: The IASLC mesothelioma staging project: Proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 11:2100–2111. 2016.PubMed/NCBI View Article : Google Scholar
16	Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallières E, Groome P, Kennedy C, Krasnik M, Peake M, Shemanski L, et al: The IASLC lung cancer staging project: External validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 12:1109–1121. 2017.PubMed/NCBI View Article : Google Scholar
17	Jett JR, Schild SE, Kesler KA and Kalemkerian GP: Treatment of small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 143:e400S–e419S. 2013.PubMed/NCBI View Article : Google Scholar
18	Adachi H, Maehara T, Nakayama H and Masuda M: Mediastinal lymph node dissection in surgical treatment for early stage non-small-cell lung cancer: Lobe-specific or systematic? J Thorac Dis. 9:2728–2731. 2017.PubMed/NCBI View Article : Google Scholar
19	Ma K, Chang D, He B, Gong M, Tian F, Hu X, Ji Z and Wang T: Radical systematic mediastinal lymphadenectomy versus mediastinal lymph node sampling in patients with clinical stage IA and pathological stage T1 non-small cell lung cancer. J Cancer Res Clin Oncol. 134:1289–1295. 2008.PubMed/NCBI View Article : Google Scholar
20	Goldstraw P: Report on the international workshop on intrathoracic staging. London, October 1996. Lung Cancer. 18:107–111. 1997.
21	Wu Y, Huang ZF, Wang SY, Yang XN and Ou W: A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer. 36:1–6. 2002.PubMed/NCBI View Article : Google Scholar
22	Keller SM, Adak S, Wagner H and Johnson DH: Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern cooperative oncology group. Ann Thorac Surg. 70:358–365; discussion 365-356. 2000.PubMed/NCBI View Article : Google Scholar
23	Misthos P, Sepsas E, Kokotsakis J, Skottis I and Lioulias A: Prognosis of stage pIIIA non small cell lung cancer after mediastinal lymph node dissection or sampling. J BUON. 14:45–49. 2009.PubMed/NCBI
24	Doddoli C, Aragon A, Barlesi F, Chetaille B, Robitail S, Giudicelli R, Fuentes P and Thomas P: Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer? Eur J Cardiothorac Surg. 27:680–685. 2005.PubMed/NCBI View Article : Google Scholar
25	Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE II, Landreneau RJ, Inculet RI, Jones DR, Meyers BF, Harpole DH, et al: Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: Initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 81:1013–1019; discussion 1019-1020. 2006.PubMed/NCBI View Article : Google Scholar
26	Bille A, Woo KM, Ahmad U, Rizk NP and Jones DR: Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients. Eur J Cardiothorac Surg. 51:674–679. 2017.PubMed/NCBI View Article : Google Scholar
27	Huang X, Wang J, Chen Q and Jiang J: Mediastinal lymph node dissection versus mediastinal lymph node sampling for early stage non-small cell lung cancer: A systematic review and meta-analysis. PLoS ONE. 9(e109979)2014.PubMed/NCBI View Article : Google Scholar
28	Watanabe S: Lymph node dissection for lung cancer: Past, present, and future. Gen Thorac Cardiovasc Surg. 62:407–414. 2014.PubMed/NCBI View Article : Google Scholar
29	Meng D, Zhou Z, Wang Y, Wang L, Lv W and Hu J: Lymphadenectomy for clinical early-stage non-small-cell lung cancer: A systematic review and meta-analysis. Eur J Cardiothorac Surg. 50:597–604. 2016.PubMed/NCBI View Article : Google Scholar
30	Samayoa AX, Pezzi TA, Pezzi CM, Gay EG, Asai M, Kulkarni N, Carp N, Chun SG and Putnam JB Jr: Rationale for a minimum number of lymph nodes removed with non-small cell lung cancer resection: Correlating the number of nodes removed with survival in 98,970 patients. Ann Surg Oncol. 23:1005–1011. 2016.PubMed/NCBI View Article : Google Scholar
31	Liang W, He J, Shen Y, Shen J, He Q, Zhang J, Jiang G, Wang Q, Liu L, Gao S, et al: Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: A population study of the US SEER database and a Chinese multi-institutional registry. J Clin Oncol. 35:1162–1170. 2017.PubMed/NCBI View Article : Google Scholar
32	Riquet M, Arame A and Pricopi C: Subcarinal lymph node importance revisited. Ann Thorac Surg. 105:666–667. 2018.PubMed/NCBI View Article : Google Scholar